BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

VOLUNTARY ANNOUNCEMENT

BIOCYTOGEN SECURES U.S. PATENT FOR THE KEY TECHNOLOGY OF FULLY HUMAN ANTIBODY MICE RENMAB™

The board (the "**Board**") of directors (the "**Director(s)**") of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**" or "**Biocytogen**", together with its subsidiaries, the "**Group**") is pleased to announce its independently self-developed key technology of fully human antibody mice RenMab™ (the "**Patent**") has received a patent certificate (No. US-11730151-B2) from the United States Patent and Trademark Office. This achievement follows the earlier issuance of a Chinese patent earlier this year. For details, please refer to the announcement dated on July 11, 2023.

RenMab mice are designed for efficient discovery of therapeutic fully human monoclonal antibodies from mice. Using the Company's independently developed Size-Unlimited and Precise Chromosome Engineering (**SUPCE**®) technology, mice are genetically engineered with *in situ* replaced full human antibody heavy and light chain variable regions to make RenMab mice. Since RenMab mice possess the complete human antibody heavy VDJ and light VJ genes, they can generate fully human antibodies with maximum diversity, increasing the success rate of antibody discovery. Moreover, the variable regions of fully human antibodies generated from RenMab mice do not require *in vitro* humanization, which de-risks the antibody development process and saves time and cost.

With the advantages in discovering fully human antibodies with low immunogenicity, high diversity, favorable affinity and excellent physiochemical properties, RenMab mice, together with Biocytogen's other fully human antibody discovery RenMice® mice platforms, have gained widespread recognition in the global biotech and biopharmaceutical industry. RenMice® platform licensing agreements have been established between the Company and dozens of companies, including Merck KGaA, Janssen, Xencor, BeiGene, Innovent, Junshi Biosciences and Remegen.

Details of the Patent are set out below:

Patent Name:	Genetically modified non-human animals with humanized immunoglobulin locus
Type:	Utility Patent
Patent Number:	US-11730151-B2
Date of Application:	October 12, 2022
Date of Expiry:	February 18, 2040

Dr. Yuelei Shen, the chairman of the Board, chief executive officer and executive Director of the Company, said: "We are glad that the core technology of our RenMab mice received both the U.S. and Chinese patents. This recognition underscores our Company's innovative capabilities and reinforces our competitive edge in the field of therapeutic antibody drug discovery. We will keep developing more innovative biologic drug discovery platforms, and actively engage in global patent strategies and protection on key technologies to continue supporting our worldwide partners with intellectual property rights protected. We look forward to obtaining more patent issuance for all RenMice family members and company's independently developed new technologies, ultimately accelerating novel drug development for the benefits of patients."

This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, December 5, 2023

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.

Biocytogen Secures U.S. Patent for the Key Technology of Fully Human Antibody Mice RenMab™

Beijing, China – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("**Biocytogen**" or "**Company**") (Stock Code: 02315.HK) announced its independently self-developed key technology of fully human antibody mice RenMab™ has received a patent certificate (No. US-11730151-B2) from the United States Patent and Trademark Office. This achievement follows the earlier issuance of a Chinese patent earlier this year.

RenMab mice are designed for efficient discovery of therapeutic fully human monoclonal antibodies from mice. Using Biocytogen's independently developed Size-Unlimited and Precise Chromosome Engineering (**SUPCE®**) technology, mice are genetically engineered with *in situ* replaced full human antibody heavy and light chain variable regions to make RenMab mice. Since RenMab mice possess the complete human antibody heavy VDJ and light VJ genes, they can generate fully human antibodies with maximum diversity, increasing the success rate of antibody discovery. Moreover, the variable regions of fully human antibodies generated from RenMab mice do not require *in vitro* humanization, which de-risks the antibody development process and saves time and cost.

With the advantages in discovering fully human antibodies with low immunogenicity, high diversity, favorable affinity and excellent physiochemical properties, RenMab mice, together with Biocytogen's other fully human antibody discovery RenMice® mice platforms, have gained widespread recognition in the global biotech and biopharmaceutical industry. RenMice® platform licensing agreements have been established between the Company and dozens of companies, including Merck KGaA, Janssen, Xencor, BeiGene, Innovent, Junshi Biosciences and Remegen.

Dr. Yuelei Shen, the chairman of the Board, chief executive officer and executive Director of the Company, said: "We are glad that the core technology of our RenMab mice received both the U.S. and Chinese patents. This recognition underscores our Company's innovative capabilities and reinforces our competitive edge in the field of therapeutic antibody drug discovery. We will keep developing more innovative biologic drug discovery platforms, and actively engage in global patent strategies and protection on key technologies to continue supporting our worldwide partners with intellectual property rights protected. We look forward to obtaining more patent issuance for all RenMice family members and company's independently developed new technologies, ultimately accelerating novel drug development for the benefits of patients."

About Biocytogen

Biocytogen (Stock Code: 02315.HK) is a global biotechnology company focused on the research and development of novel antibody-based drugs. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/RenLite®/RenNano®/RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1,000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (**MNCs**). Biocytogen's pipeline is comprised of 10 core assets, with partnerships also established for multiple clinical assets. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides 1,700+ off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg).

For more information, please visit our website at **http://en.biocytogen.com.cn**.

Forward-Looking Statements

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.